Search - tctmd.com

Displaying 1 - 9 of 9

Sort: Relevancy | Date

News Industry News

Robocath raises €5 million and announces the appointment of Lucien Goffart as new CEO

September 03, 2019

News Industry News

Biofourmis' RhythmAnalytics™ Platform Receives FDA Clearance for AI-Based Automated Interpretation of Cardiac Arrhythmias

April 30, 2019

News Industry News

Robocath obtains CE marking for R-One™, its robotic-assisted solution for treating coronary diseases

February 26, 2019

News Industry News

Robocath’s R-One™ robot acquired by the Medical Training & Testing Center in Rouen for future healthcare practitioner training

January 22, 2019

News Industry News

Doctor's Best Introduces Two New Heart Health Supplements

August 11, 2015

News Industry News

Amarin Reaffirms Its Mission to Improve Patient Care With Commitment to Completing REDUCE-IT Cardiovascular Outcomes Study

September 16, 2014

News Industry News

Amarin Announces Publication of Case Study Results Describing Reductions in Multiple Lipid Parameters for Individual Hyperlipidemic Patients Switched to Vascepa(R)

June 11, 2014

News Industry News

US FDA approves EPANOVA for the treatment of adults with severe hypertriglyceridaemia

May 06, 2014

News Industry News

Pivotal Therapeutics exhibiting at European Society of Cardiology Congress 2012

August 23, 2012

Advertisement

Robocath raises €5 million and announces the appointment of Lucien Goffart as new CEO

Biofourmis' RhythmAnalytics™ Platform Receives FDA Clearance for AI-Based Automated Interpretation of Cardiac Arrhythmias

Robocath obtains CE marking for R-One™, its robotic-assisted solution for treating coronary diseases

Robocath’s R-One™ robot acquired by the Medical Training & Testing Center in Rouen for future healthcare practitioner training

Doctor's Best Introduces Two New Heart Health Supplements

Amarin Reaffirms Its Mission to Improve Patient Care With Commitment to Completing REDUCE-IT Cardiovascular Outcomes Study

Amarin Announces Publication of Case Study Results Describing Reductions in Multiple Lipid Parameters for Individual Hyperlipidemic Patients Switched to Vascepa(R)

US FDA approves EPANOVA for the treatment of adults with severe hypertriglyceridaemia

Pivotal Therapeutics exhibiting at European Society of Cardiology Congress 2012

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content